Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.
暂无分享,去创建一个
J. Maciejewski | H. Carraway | A. Advani | M. Sekeres | M. Kalaycio | A. Nazha | T. Radivoyevitch | S. Mukherjee | A. Gerds | R. Molenaar | D. Adelstein | S. Sidana | N. Majhail | C. Nasr | Remco J. Molenaar | D. Angelini
[1] S. Devesa,et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013 , 2017, JAMA.
[2] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[3] V. Klimek,et al. Therapy-related myeloid neoplasms: what's in a name? , 2016, Current opinion in hematology.
[4] D. Brenner,et al. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation , 2016, Leukemia.
[5] Tzeng-Ji Chen,et al. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study. , 2016, Journal of the National Cancer Institute.
[6] S. Mandel,et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[7] R. Pathak,et al. Therapy-related acute myeloid leukemia following radioactive iodine treatment for thyroid cancer , 2015, Cancer Causes & Control.
[8] R. ShahaAshok,et al. The 2009 American Thyroid Association Guidelines Modestly Reduced Radioactive Iodine Use for Thyroid Cancers Less Than 1 cm , 2014 .
[9] J. Shah,et al. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1 cm. , 2014, Thyroid : official journal of the American Thyroid Association.
[10] S. Bakker,et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Miao-Fen Chen,et al. Second primary malignancies following thyroid cancer: a population-based study in Taiwan. , 2013, European journal of endocrinology.
[12] S. Larson,et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. , 2013, Thyroid : official journal of the American Thyroid Association.
[13] H. Sugiyama,et al. The Incidence of Leukemia, Lymphoma and Multiple Myeloma among Atomic Bomb Survivors: 1950–2001 , 2013, Radiation research.
[14] T. Prebet,et al. Acute leukemia arising after radioiodine treatment for thyroid cancer , 2012, Haematologica.
[15] R. Schlenk,et al. Therapy-related myeloid neoplasms following treatment with radioiodine , 2012, Haematologica.
[16] I. Ganly,et al. Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy , 2011, Cancer.
[17] J. Griggs,et al. Use of radioactive iodine for thyroid cancer. , 2011, JAMA.
[18] Douglas G Altman,et al. How to obtain the confidence interval from a P value , 2011, BMJ : British Medical Journal.
[19] F. Aversa,et al. Regression modeling of competing risk using R: an in depth guide for clinicians , 2010, Bone Marrow Transplantation.
[20] S. Straus,et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. , 2009, Thyroid : official journal of the American Thyroid Association.
[21] J. Tward,et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.
[22] A. Gafni,et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. , 2007, Thyroid : official journal of the American Thyroid Association.
[23] M. McBride,et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. , 2006, The Journal of clinical endocrinology and metabolism.
[24] E. Ron,et al. Thyroid cancer and multiple primary tumors in the SEER cancer registries 1 , 2005, International journal of cancer.
[25] P. Hall,et al. Second primary malignancies in thyroid cancer patients , 2003, British Journal of Cancer.
[26] I. Shimon,et al. Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature , 1995, Clinical endocrinology.
[27] M. Ranney,et al. Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.
[28] S. M. Seidlin,et al. Acute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinoma. , 1956, Science.